Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.
Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL, Berman DM, Nifong TP, Blume-Jensen P. Shipitsin M, et al. Among authors: blume jensen p. Proteome Sci. 2014 Jul 12;12:40. doi: 10.1186/1477-5956-12-40. eCollection 2014. Proteome Sci. 2014. PMID: 25075204 Free PMC article.
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.
Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P. Shipitsin M, et al. Among authors: blume jensen p. Br J Cancer. 2014 Sep 9;111(6):1201-12. doi: 10.1038/bjc.2014.396. Epub 2014 Jul 17. Br J Cancer. 2014. PMID: 25032733 Free PMC article.
Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.
Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, Small C, Choudhury S, Capela T, Coupal L, Ernst C, Hurley A, Kaprelyants A, Chang H, Giladi E, Nardone J, Dunyak J, Loda M, Klein EA, Magi-Galluzzi C, Latour M, Epstein JI, Kantoff P, Saad F. Blume-Jensen P, et al. Clin Cancer Res. 2015 Jun 1;21(11):2591-600. doi: 10.1158/1078-0432.CCR-14-2603. Epub 2015 Mar 2. Clin Cancer Res. 2015. PMID: 25733599
Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs.
Golder MR, Liu J, Andersen JN, Shipitsin MV, Vohidov F, Nguyen HV, Ehrlich DC, Huh SJ, Vangamudi B, Economides KD, Neenan AM, Ackley JC, Baddour J, Paramasivan S, Brady SW, Held EJ, Reiter LA, Saucier-Sawyer JK, Kopesky PW, Chickering DE, Blume-Jensen P, Johnson JA. Golder MR, et al. Among authors: blume jensen p. Nat Biomed Eng. 2018 Nov;2(11):822-830. doi: 10.1038/s41551-018-0279-x. Epub 2018 Aug 20. Nat Biomed Eng. 2018. PMID: 30918745 Free PMC article.
Publisher Correction: Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs.
Golder MR, Liu J, Andersen JN, Shipitsin MV, Vohidov F, Nguyen HV, Ehrlich DC, Huh SJ, Vangamudi B, Economides KD, Neenan AM, Ackley JC, Baddour J, Paramasivan S, Brady SW, Held EJ, Reiter LA, Saucier-Sawyer JK, Kopesky PW, Chickering DE, Blume-Jensen P, Johnson JA. Golder MR, et al. Among authors: blume jensen p. Nat Biomed Eng. 2018 Sep;2(9):707. doi: 10.1038/s41551-018-0299-6. Nat Biomed Eng. 2018. PMID: 31015683
Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities.
Vohidov F, Andersen JN, Economides KD, Shipitsin MV, Burenkova O, Ackley JC, Vangamudi B, Nguyen HV, Gallagher NM, Shieh P, Golder MR, Liu J, Dahlberg WK, Ehrlich DJC, Kim J, Kristufek SL, Huh SJ, Neenan AM, Baddour J, Paramasivan S, de Stanchina E, Kc G, Turnquist DJ, Saucier-Sawyer JK, Kopesky PW, Brady SW, Jessel MJ, Reiter LA, Chickering DE, Johnson JA, Blume-Jensen P. Vohidov F, et al. Among authors: blume jensen p. J Am Chem Soc. 2021 Mar 31;143(12):4714-4724. doi: 10.1021/jacs.1c00312. Epub 2021 Mar 19. J Am Chem Soc. 2021. PMID: 33739832 Free PMC article.
Identification of direct target engagement biomarkers for kinase-targeted therapeutics.
Paweletz CP, Andersen JN, Pollock R, Nagashima K, Hayashi ML, Yu SU, Guo H, Bobkova EV, Xu Z, Northrup A, Blume-Jensen P, Hendrickson RC, Chi A. Paweletz CP, et al. Among authors: blume jensen p. PLoS One. 2011;6(10):e26459. doi: 10.1371/journal.pone.0026459. Epub 2011 Oct 24. PLoS One. 2011. PMID: 22039492 Free PMC article.
PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.
Ellwood-Yen K, Keilhack H, Kunii K, Dolinski B, Connor Y, Hu K, Nagashima K, O'Hare E, Erkul Y, Di Bacco A, Gargano D, Shomer NH, Angagaw M, Leccese E, Andrade P, Hurd M, Shin MK, Vogt TF, Northrup A, Bobkova EV, Kasibhatla S, Bronson RT, Scott ML, Draetta G, Richon V, Kohl N, Blume-Jensen P, Andersen JN, Kraus M. Ellwood-Yen K, et al. Among authors: blume jensen p. Cancer Res. 2011 Apr 15;71(8):3052-65. doi: 10.1158/0008-5472.CAN-10-2282. Cancer Res. 2011. PMID: 21493594
Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.
Nagashima K, Shumway SD, Sathyanarayanan S, Chen AH, Dolinski B, Xu Y, Keilhack H, Nguyen T, Wiznerowicz M, Li L, Lutterbach BA, Chi A, Paweletz C, Allison T, Yan Y, Munshi SK, Klippel A, Kraus M, Bobkova EV, Deshmukh S, Xu Z, Mueller U, Szewczak AA, Pan BS, Richon V, Pollock R, Blume-Jensen P, Northrup A, Andersen JN. Nagashima K, et al. Among authors: blume jensen p. J Biol Chem. 2011 Feb 25;286(8):6433-48. doi: 10.1074/jbc.M110.156463. Epub 2010 Nov 30. J Biol Chem. 2011. PMID: 21118801 Free PMC article.
28 results